ESMO - Eur. Oncology· @myESMO · X·· 18 小时前评分45
正文 · 机器翻译
#ESMO26：正如 Funda Meric-Bernstam 所讨论的，pumitamig 等在研双特异性抗体（如抗 PD-L1/VEGF-A 的 pumitamig）与抗体偶联药物（#ADCs）联合治疗晚期实体瘤时正展现出潜力
🔗 https://ow.ly/l98f50ZZkgJ
#InsightsbyESMO
199 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1963P按 Investigational immunotherapy 对上
First-in-human phase I study of GB268, a tri-specific antibody targeting PD-1, CTLA-4 and VEGF in advanced solid tumours
https://esmocongress.esmo.org2660P按 NSCLC, metastatic 对上
Phase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results
https://esmocongress.esmo.org3636TIP按 Renal cancer 对上
LITESPARK-034: Phase 3 study of belzutifan plus zanzalintinib versus belzutifan in participants with advanced renal cell carcinoma (RCC) during or after anti-PD-(L)1 therapy and VEGF-TKI
https://esmocongress.esmo.org来源：ESMO - Eur. Oncology · x.com